11:48 AM
 | 
Mar 20, 2019
 |  BC Extra  |  Preclinical News

Peptomyc study details MYC-targeted cell-penetrating biologic

A new study from Peptomyc provides the latest evidence that cell-penetrating biologics can hit the previously intractable cancer target MYC. In a Science Translational Medicine paper, the company showed its mini-protein targeting MYC can reach the nucleus of cancer cells, block MYC's transcriptional activity and suppress tumor growth.

MYC is one of a handful of intracellular cancer proteins that have been notoriously difficult to target with small molecules because they lack defined binding pockets. While biologics don't require the same defined binding pocket, delivering large proteins into the cell has been challenging.

Targeting MYC is especially challenging because three family members -- c-Myc, n-Myc and l-Myc -- all need to be blocked for...

Read the full 547 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >